- Galecto Inc (NASDAQ:GLTO) has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.
- Myelofibrosis, a form of chronic leukemia, is a rare type of blood cancer in which the normal bone marrow is destroyed by fibrous scar tissue that does not produce blood cells.
- The open-label MYLOX-1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GB2064 in 16 patients over 9 months.
- The trial will also assess the impact on fibrosis and quantification of the tissue targeting of GB2064 and other aspects of clinical response in myelofibrosis.
- Price Action: GLTO shares are up 5.4% at $4.08 during the premarket session on the last check Wednesday.
NanoViricides Shares Unaffected As Traders Circulate Seeking Alpha Blogpost From Contributor White Diamond Research ‘NanoViricides Will Return To $3-$5 As Soon As The Coronavirus Newsflow Fades’
https://seekingalpha.com/article/4320691-nanoviricides-will-return-to-3-5-soon-coronavirus-newsflow-fades
